Adalimumab and number of previous biological disease-modifying antirheumatic drugs as predictive factors for the development of immune-mediated skin lesions

Martins, A.; Oliveira, D. Santos; Martins, F. R.; Nicolau, R.; Pinheiro, F. Oliveira; Rato, M.; Bernardo, A.; Pimenta, S.; Bernardes, M.; Costa, L.

http://hdl.handle.net/10400.1/26910

Utilize este identificador para referenciar este registo.

Nome:	Descrição:	Tamanho:	Formato:
ADALIMUMAB AND NUMBER OF PREVIOUS BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AS PREDICTIVE FACTORS FOR THE DEVELOPMENT OF IMMUNE-MEDIATED SKIN LESIONS.pdf		240.85 KB	Adobe PDF	Ver/Abrir

Contacte-nos

Autores

Pinheiro, F. Oliveira

Resumo(s)

Treatment of inflammatory rheumatic diseases has dramatically changed with the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDs). However, these drugs aren’t exempt from risks and skin lesions are the most frequent adverse reactions. Among the possible adverse skin reactions, immune-mediated skin lesions (IMSL) may occur. Risk factors associated with the occurrence of IMSL in rheumatic patients under bDMARDs are poorly known and studied.

Descrição

European Congress of Rheumatology (EULAR)

Palavras-chave

Skin bDMARD

URI

http://hdl.handle.net/10400.1/26910

Editora

Elsevier

DOI

10.1136/annrheumdis-2023-eular.2061

Coleções

ULS_10.2-MED-Conferências

Licença CC

cclicense-by

Métricas Alternativas

Ver registo completo